Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell Carcinoma

NCT06399419 is registered in ClinicalTrials.gov with Osel, Inc. as lead sponsor.

NCT NCT06399419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell Carcinoma
Lead sponsor
Osel, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 19, 2024
Completion date
October 19, 2026
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, advanced renal cell carcinoma, advanced sarcomatoid renal cell carcinoma, metastatic clear cell renal cell carcinoma, metastatic renal cell carcinoma, metastatic sarcomatoid renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8